Summer 2026

Business Data Analytics Intern

Channel Coverage

Posted on 5/24/2026

Becton Dickinson

Becton Dickinson

10,001+ employees

Global medical devices and diagnostics provider

Compensation Overview

$23.96 - $33.54/hr

New Mexico, USA + 51 more

More locations: Washington, USA | Kansas, USA | Pennsylvania, USA | North Dakota, USA | Oregon, USA | Delaware, USA | Iowa, USA | Milpitas, CA, USA | California, USA | Washington, DC, USA | Vermont, USA | Wyoming, USA | Texas, USA | Montana, USA | Jackson Township, NJ, USA | Florida, USA | Waterbury, CT, USA | Nevada, USA | South Carolina, USA | South Dakota, USA | Georgia, USA | Arizona, USA | Concord, NH, USA | Mississippi, USA | Tennessee, USA | Virginia, USA | Arkansas, USA | Minnesota, USA | Colorado, USA | Nebraska, USA | Rhode Island, USA | Utah, USA | Hawaii, United States | Kentucky, USA | West Virginia, USA | New York, NY, USA | Maryland, USA | Wisconsin, USA | Maine, USA | Massachusetts, USA | North Carolina, USA | Oklahoma, USA | Missouri, USA | Ohio, USA | Indiana, USA | Louisiana, USA | Alaska, USA | Michigan, USA | Illinois, USA | Alabama, USA | Idaho, USA

Hybrid

Minimum 4 days in-office per week.

Category
Data & Analytics
Required Skills
Python
R
SQL
Data Analysis
Excel/Numbers/Sheets
Requirements
  • Current Bachelor's degree student.
  • Strong analytical and quantitative skills, with hands-on experience working with real-world business data, including data extraction, cleansing, validation, and preparation for analysis and basic modeling.
  • Proficiency with analytical tools such as Excel, SQL, Python, R, or comparable platforms.
  • Demonstrated ability to translate complex datasets into clear, actionable business insights.
  • Strong written and verbal communication skills, with the ability to effectively engage cross-functional stakeholders.
  • Interest in life sciences, diagnostics, analytical instrumentation, or healthcare markets.
  • Self-starter with strong attention to detail and the ability to work independently in a fast-paced, matrixed environment.
Responsibilities
  • Design, develop, and implement a data-driven framework to identify, evaluate, and select business partners in support of a unified channel coverage model across Waters and BD.
  • Partner closely with sales, marketing, commercial excellence, and product management teams across both organizations to align on data requirements, validate assumptions, and ensure the model meets operational and commercial needs.
  • Gather, integrate, and analyze diverse data sources, including sales history, installed base data, product portfolio, market coverage, and organizational structures.
  • Develop dashboards and visualizations that clearly synthesize insights and effectively communicate recommendations to stakeholders.
  • Prepare and deliver weekly progress updates highlighting key accomplishments, risks, and next steps.
  • Document analytical assumptions, data sources, and model logic to ensure transparency, scalability, and continuity beyond the duration of the internship.
Desired Qualifications
  • Current MBA or Master’s degree student with a concentration in Business Analytics, Data Science, Marketing Analytics, or a related field.
  • Experience with data visualization tools (e.g., Power BI, Tableau) and/or machine learning techniques.

BD is a global medical technology company serving hospitals, labs, and healthcare providers with products across BD Medical, Life Sciences, and Interventional. Its offerings include medication management and delivery devices, safe specimen collection and transport systems, and minimally invasive surgical instruments. Its products help safe medication administration, preserve specimen integrity for diagnostics, and enable less-invasive procedures, saving time and improving outcomes. BD differentiates itself with a broad end-to-end portfolio, global reach, and focus on quality, safety, and service to support care across regions; its goal is to improve patient outcomes, lower costs, and increase efficiency in care environments.

Company Size

10,001+

Company Stage

IPO

Headquarters

Franklin Lakes, New Jersey

Founded

1961

Simplify Jobs

Simplify's Take

What believers are saying

  • Wellstar deployment validates BD Pyxis Pro and Alaris in enterprise medication management.[3]
  • Elyra expands BD’s urology franchise with kidney-stone and soft-tissue applications.[3]
  • Saudi Arabia headquarters and manufacturing plans support regional growth and localization.[3]

What critics are saying

  • Life Sciences weakness in U.S. point-of-care and China still weighs on results.
  • Higher debt from the €600 million notes constrains flexibility if growth disappoints.
  • Interventional execution must offset lost Biosciences earnings after the Waters divestiture.

What makes Becton Dickinson unique

  • BD is a pure-play medical technology company after the Waters Biosciences spin-off.[3][4]
  • Its portfolio spans Medical, Life Sciences, and Interventional across care delivery.[1][3]
  • BD combines smart devices, automation, AI, and analytics in connected care.[3]

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Becton Dickinson who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Tuition Reimbursement

Company News

الاقتصادية
May 21st, 2026
BD moves its regional headquarters to Saudi Arabia to invest in digital health transformation

BD moves its regional headquarters to Saudi Arabia to invest in digital health transformation Nezih Darwish, president of BD for the Middle East, Turkey, and Africa, confirmed that the decision to establish the company's regional headquarters in Riyadh is not merely an administrative expansion but is part of the company's strategy to strengthen its presence in the region, amid Saudi Arabia's accelerating transformations in the healthcare sector. In statements to Al-Eqtisadiah, Darwish said that the company's presence in Saudi Arabia places it at the heart of one of the most ambitious health transformation programs globally, explaining that this presence gives the company a greater ability to understand the needs of the health sector up close and enhance cooperation with the Ministry of Health and regulatory bodies, ensuring that the technologies and solutions the company provides align with the kingdom's national priorities. He added that expansion plans include several tracks, including developing the regional headquarters' business, investing in training and education through the 'BD Training Center' and the 'BD Digital Education Academy' platform, along with progress in local manufacturing plans aimed at enhancing supply chain resilience. He added that the regional headquarters in Riyadh also contributes to accelerating the transfer of knowledge and expertise to healthcare sector workers through specialized training programs, most notably the 'BD Training Center', which focuses on raising the efficiency of doctors, surgeons, pharmacists, nursing staff, laboratory technicians, and phlebotomists, supporting the effective use of modern medical technologies within healthcare facilities. He pointed out that the company's presence in Saudi Arabia also reflects a long-term commitment to the Saudi market, supports attracting talent and investments to the biotechnology and medical technology sectors, along with enhancing the company's ability to manage its regional operations and provide commercial support to regional markets from Riyadh. Plans for expansion and local manufacturing Darwish explained that Saudi Arabia is among the company's strategic priorities, noting that BD is currently studying opportunities to expand its operational and manufacturing operations within the kingdom, in line with the targets of Saudi Vision 2030 to localize industries and enhance local content. He explained that by building these capabilities within the kingdom, the company aims to facilitate faster access for healthcare facilities to advanced medical technologies and contribute to local economic development, confirming that the company's vision is not limited to increasing the volume of operations but includes building a sustainable ecosystem based on innovative solutions, qualified competencies, and effective partnerships to support the development of the healthcare sector in Saudi Arabia. He affirmed that the company's investments in Saudi Arabia are part of a long-term commitment to the local market, through which it seeks to achieve added value for the health sector, support the national economy by providing job opportunities, developing local capabilities, transferring modern technologies and expertise, in addition to contributing to enhancing the health infrastructure and raising the sector's ability to achieve higher levels of self-sufficiency and competitiveness. Digital transformation and artificial intelligence Darwish explained that investment in medical technology plays a key role in developing the health sector and supporting the economic diversification efforts adopted by Saudi Arabia under Vision 2030, noting that the kingdom has allocated significant investments to develop the healthcare system and transition from the traditional high-cost treatment model to a model that focuses more on prevention, early detection, and the use of modern technologies in supporting medical decision-making. He added that these technologies help doctors detect health risks early and choose appropriate therapeutic interventions for each case, contributing to improving patient outcomes, reducing complications, and lowering rates of hospital readmission, while raising the efficiency of the health system in general. Investment opportunities in healthcare Darwish said that Saudi Arabia is implementing one of the largest health investment plans globally, with a trend to increase the private sector's contribution to hospital capacity by 2030, which enhances the importance of advanced medical technologies, especially in the areas of digital health services, artificial intelligence, and connected healthcare models. He added that the Saudi market is poised to attract more investments in the fields of smart hospitals, health data exchange platforms, and clinical technologies supporting early prevention and personalized care, noting that public-private partnerships contribute to accelerating the adoption of these solutions within the health system. Medical technologies and healthcare development Darwish stressed that innovative medical technologies and solutions have become a fundamental element in developing healthcare in Saudi Arabia, especially with the expected population growth in the coming years, explaining that the true value of these solutions lies in their ability to connect patient data with daily work flows within healthcare facilities and transform data into information that helps medical teams provide faster and more efficient care. He explained that these solutions include technologies for intelligent search, health data analysis, and tracking at the level of the health system or various medical departments, helping information reach the relevant teams at the right time. Supporting national competencies and supply chains Darwish said that BD seeks to contribute to developing the future of healthcare in Saudi Arabia and the region by participating in building more efficient, interconnected, and future-ready health systems, by providing solutions that help healthcare providers improve service quality and make accurate decisions at the right time. He added that the company is also working to support localization efforts, strengthen supply chains, build local capabilities, invest in training health cadres, in addition to cooperating with national entities, foremost among them the Ministry of Health, in initiatives related to patient safety and applying best practices within the health system. He affirmed that the company continues to work with its partners in Saudi Arabia and the region to provide practical solutions that contribute to raising the efficiency of the health sector, improving the quality of healthcare, and enhancing its long-term sustainability.

Yahoo Finance
Apr 14th, 2026
BD reports Q2 earnings with 6% revenue growth but organic sales miss expectations at 0.9%

Becton Dickinson reported second-quarter fiscal 2025 results with revenue growing 6%, or 0.9% organically, falling below expectations. The medical device company cited market challenges in its Life Sciences segment, including changes in research funding policy and slower-than-expected recovery in blood culture testing within Diagnostics. Chairman and CEO Tom Polen acknowledged dissatisfaction with the top-line performance, noting it doesn't reflect the mid-single-digit growth BD has consistently delivered in recent years. The company is implementing strategic actions and investments to reaccelerate organic sales growth. Despite revenue challenges, BD exceeded adjusted earnings per share expectations, delivering adjusted gross margins of 54.9%, up 190 basis points year-over-year. This marks the fourth consecutive quarter of strong gross margin expansion driven by the company's BD Excellence initiative.

PR Newswire
Apr 9th, 2026
Rick Byrd to retire from BD.

Rick Byrd to retire from BD. Apr 09, 2026, 16:05 ET FRANKLIN LAKES, N.J., April 9, 2026 /PRNewswire/ - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Richard (Rick) Byrd has informed the company of his intent to retire after nearly 25 years with BD. Byrd is currently executive vice president and president of the Interventional Segment at BD, a position he has held since September 2022. During his tenure, Byrd held several leadership roles including worldwide president of Medication Delivery Solutions and worldwide president of Preanalytical Systems. Prior to joining BD in 2004, Byrd held various leadership and engineering positions across the medical device and advanced technology sectors. "Over his long career, Rick has led his teams to deliver meaningful results for BD - strengthening our portfolio, elevating our operational rigor and advancing BD's role as a global healthcare leader," said Tom Polen, chairman, CEO and president of BD. "Rick has driven impact across multiple segments, including expanding BD's leadership in Vascular Access Management, advancing our 'One-Stick Hospital Stay' vision and leading critical manufacturing scale-up efforts during the COVID-19 pandemic. We thank Rick for his many contributions to BD and wish him all the best in his retirement." Byrd will remain in his role through June. BD intends to name a successor prior to Byrd's retirement date. "What has inspired me most throughout my time at BD is the people - the teams who show up every day committed to driving the future of care and improving outcomes for patients everywhere," Byrd said. "I'm incredibly proud of the meaningful work we've accomplished together and am confident that BD will continue to deliver on its purpose of advancing the world of health." About BD BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health(TM) by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson. | Contacts: | / | | Media | Investors | | Megan Dubrowski Senior Director, Executive Communications [email protected] | Shawn Bevec SVP, Investor Relations [email protected] | SOURCE BD (Becton, Dickinson and Company)

PR Newswire
Apr 8th, 2026
BD gains CE Mark for adjustable Liverty TIPS Stent Graft in EU portal hypertension care

BD has received CE Mark approval for its Liverty TIPS Stent Graft, bringing next-generation portal hypertension treatment to the European Union. The device features an adjustable 6–10mm inner diameter and offers the broadest range of covered stent lengths currently available for transjugular intrahepatic portosystemic shunt procedures. Designed for patients with cirrhosis complications, the device uses a flexible nitinol frame and dual-layer ePTFE encapsulation delivered via a triaxial system. An estimated 58 million people worldwide live with cirrhosis, which can lead to life-threatening portal hypertension complications. Safety and effectiveness data from the pivotal ARCH clinical trial will be presented at the Society of Interventional Radiology Annual Scientific Meeting on 12 April 2026. The device remains investigational in the United States.

BD
Apr 8th, 2026
BD delivers next-generation TIPS innovation to advance portal hypertension care across the European Union.

BD delivers next-generation TIPS innovation to advance portal hypertension care across the European Union. CE Marking and ARCH clinical trial data position the Liverty(TM) TIPS Stent Graft to expand treatment options for patients with advanced liver disease FRANKLIN LAKES, N.J., April 8, 2026 /PRNewswire/ - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced application of CE Mark for the Liverty(TM) TIPS Stent Graft, delivering innovation to portal hypertension care across the European Union. Designed to expand treatment options for patients with cirrhosis and complications of portal hypertension, our next-generation, adjustable-diameter device represents the latest advancement by BD in interventional therapies addressing complex liver disease. Safety and effectiveness data from the pivotal ARCH clinical trial evaluating the Liverty(TM) TIPS Stent Graft will be presented for the first time at the Society of Interventional Radiology (SIR) Annual Scientific Meeting on April 12, 2026. Cirrhosis remains a significant global health challenge, with an estimated 58 million people worldwide living with the disease, according to the latest findings from the Global Burden of Disease study.[1] Cirrhosis can lead to portal hypertension, a serious condition that can result in life-threatening complications such as variceal bleeding and fluid build-up in the abdomen or chest. [2] Transjugular intrahepatic portosystemic shunt (TIPS) procedures help reduce symptoms caused by elevated portal pressure by lowering that pressure and improving blood flow. The Liverty(TM) TIPS Stent Graft is engineered to support individualized patient management, offering a 6-10 mm adjustable inner diameter and the broadest range of covered TIPS stent lengths currently available. Key features include a flexible, self-expanding nitinol frame and dual-layer ePTFE encapsulation with carbon impregnation on the inner surface, delivered fully constrained on a triaxial delivery system designed for placement accuracy, control and ease of use. "For patients living with complications of portal hypertension, access to safe, effective and adaptable treatment options is critical," said Rima Alameddine, worldwide president of Peripheral Intervention at BD. "With CE Marking of the Liverty(TM) TIPS Stent Graft, we're introducing an innovative, adjustable solution that helps physicians personalize therapy and improve the potential for long-term outcomes." BD also announced that data from the ARCH clinical study, a global, prospective, multi-center, single-arm clinical study assessing the safety and effectiveness of the Liverty(TM) TIPS Stent Graft for the treatment of complications from portal hypertension, will be presented for the first time on podium by Global Principal Investigator Prof. Ziv Haskal, MD, at SIR in April. "The Liverty(TM) TIPS Stent Graft represents an important advancement in how we care for patients with the serious complications of portal hypertension," said Dr. Haskal. "Its adjustable diameter and delivery design allow physicians to better match the shunt to a patient's unique physiology, a key consideration in safe and effective TIPS creation. The trial provides the first and only prospective data describing the results of small diameter calibrated TIPS for treating all the major complications of portal hypertension. I look forward to presenting the ARCH study results at SIR." In the United States, the Liverty(TM) TIPS Stent Graft it is an investigational device limited by U.S. law to investigational use only. About BD BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health(TM) by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson. ________________________________ [1] Duo H, You J, Du S, Yu M, Wu S, Yue P, et al. Liver cirrhosis in 2021: Global Burden of Disease study. PLOS One. 2025;20(7):e0328493. doi: 10.1371/journal.pone.032849 [2] Carroll A, Boike JR. Tips for TIPS recipients: A patient-focused guidance on TIPS. Clin Liver Dis (Hoboken). 2024;23(1):e0091. doi:10.1097/CLD.0000000000000091 SOURCE BD (Becton, Dickinson and Company) Released April 8, 2026